IFRX
Price
$0.79
Change
-$0.02 (-2.47%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
54.73M
31 days until earnings call
RCUS
Price
$8.23
Change
+$0.28 (+3.52%)
Updated
Jun 30, 02:48 PM (EDT)
Capitalization
841.79M
31 days until earnings call
Interact to see
Advertisement

IFRX vs RCUS

Header iconIFRX vs RCUS Comparison
Open Charts IFRX vs RCUSBanner chart's image
InflaRx
Price$0.79
Change-$0.02 (-2.47%)
Volume$779
Capitalization54.73M
Arcus Biosciences
Price$8.23
Change+$0.28 (+3.52%)
Volume$2.18K
Capitalization841.79M
IFRX vs RCUS Comparison Chart in %
Loading...
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IFRX vs. RCUS commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IFRX is a Hold and RCUS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (IFRX: $0.81 vs. RCUS: $7.95)
Brand notoriety: IFRX and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IFRX: 28% vs. RCUS: 307%
Market capitalization -- IFRX: $54.73M vs. RCUS: $841.79M
IFRX [@Biotechnology] is valued at $54.73M. RCUS’s [@Biotechnology] market capitalization is $841.79M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IFRX’s FA Score shows that 0 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • IFRX’s FA Score: 0 green, 5 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, IFRX is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IFRX’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 2 bullish TA indicator(s).

  • IFRX’s TA Score: 5 bullish, 4 bearish.
  • RCUS’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, IFRX is a better buy in the short-term than RCUS.

Price Growth

IFRX (@Biotechnology) experienced а +1.58% price change this week, while RCUS (@Biotechnology) price change was -7.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +32.93%, and the average quarterly price growth was +6.81%.

Reported Earning Dates

IFRX is expected to report earnings on Jul 31, 2025.

RCUS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($842M) has a higher market cap than IFRX($54.7M). RCUS YTD gains are higher at: -46.608 vs. IFRX (-67.296). IFRX has higher annual earnings (EBITDA): -44.22M vs. RCUS (-377M). RCUS has more cash in the bank: 997M vs. IFRX (65.9M). IFRX has less debt than RCUS: IFRX (703K) vs RCUS (60M). RCUS has higher revenues than IFRX: RCUS (141M) vs IFRX (130K).
IFRXRCUSIFRX / RCUS
Capitalization54.7M842M6%
EBITDA-44.22M-377M12%
Gain YTD-67.296-46.608144%
P/E RatioN/AN/A-
Revenue130K141M0%
Total Cash65.9M997M7%
Total Debt703K60M1%
FUNDAMENTALS RATINGS
IFRX vs RCUS: Fundamental Ratings
IFRX
RCUS
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6588
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/a44

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCUS's Valuation (52) in the Pharmaceuticals Major industry is in the same range as IFRX (63) in the Biotechnology industry. This means that RCUS’s stock grew similarly to IFRX’s over the last 12 months.

RCUS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as IFRX (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to IFRX’s over the last 12 months.

RCUS's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as IFRX (97) in the Biotechnology industry. This means that RCUS’s stock grew similarly to IFRX’s over the last 12 months.

IFRX's Price Growth Rating (65) in the Biotechnology industry is in the same range as RCUS (88) in the Pharmaceuticals Major industry. This means that IFRX’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as IFRX (100) in the Biotechnology industry. This means that RCUS’s stock grew similarly to IFRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IFRXRCUS
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
75%
Momentum
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
76%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 4 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BIIGX36.480.30
+0.83%
Buffalo Growth Institutional
VSQCX17.200.13
+0.76%
Invesco MSCI World SRI Index C
PRSRX54.040.23
+0.43%
Putnam Research R
ITCTX29.290.06
+0.21%
VY® T. Rowe Price Capital Apprec S2
GLPRX34.510.02
+0.06%
Goldman Sachs MLP Energy Infras R

IFRX and

Correlation & Price change

A.I.dvisor tells us that IFRX and LXEO have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IFRX and LXEO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IFRX
1D Price
Change %
IFRX100%
-2.98%
LXEO - IFRX
29%
Poorly correlated
-1.44%
RCUS - IFRX
28%
Poorly correlated
-6.47%
VERA - IFRX
28%
Poorly correlated
-2.75%
NMRA - IFRX
26%
Poorly correlated
-5.32%
ARWR - IFRX
26%
Poorly correlated
+0.06%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-6.47%
XNCR - RCUS
49%
Loosely correlated
-3.10%
ACLX - RCUS
48%
Loosely correlated
+0.90%
APGE - RCUS
48%
Loosely correlated
N/A
IMNM - RCUS
48%
Loosely correlated
-0.23%
TRDA - RCUS
47%
Loosely correlated
-1.57%
More